Yondelis STS . More Recently, Trabectedin has Shown Similar Progression-Free Survival to Doxorubicin in the First-Line Setting and Significant Activity in Liposarcoma and Leiomyosarcoma Subtypes.

Trabectedin in Soft Tissue Sarcomas.

Oncoloigos :
* Petek BJ.
* Loggers ET.
* Pollack SM.
* Jones RL.

Centros :
* University of Washington.
* Fred Hutchinson Cancer Research Center, University of Washington.

Abstract :

Soft tissue sarcomas are a group of rare tumors derived from mesenchymal tissue, accounting for about 1% of adult cancers. There are over 60 different histological subtypes, each with their own unique biological behavior and response to systemic therapy.

The outcome for patients with metastatic soft tissue sarcoma is poor with few available systemic treatment options. For decades, the mainstay of management has consisted of doxorubicin with or without ifosfamide.

Trabectedin is a synthetic agent derived from the Caribbean tunicate, Ecteinascidia turbinata. This drug has a number of potential mechanisms of action, including binding the DNA minor groove, interfering with DNA repair pathways and the cell cycle, as well as interacting with transcription factors. Several phase II trials have shown that trabectedin has activity in anthracycline and alkylating agent-resistant soft tissue sarcoma and suggest use in the second- and third-line setting. More recently, trabectedin has shown similar progression-free survival to doxorubicin in the first-line setting and significant activity in liposarcoma and leiomyosarcoma subtypes

Trabectedin has shown a favorable toxicity profile and has been approved in over 70 countries for the treatment of metastatic soft tissue sarcoma. This manuscript will review the development of trabectedin in soft tissue sarcomas.